Clinical Trial Detail

NCT ID NCT03409458
Title A Dose Escalation and Confirmation Study of PT-112 in Advanced Solid Tumors in Combination With Avelumab (PAVE-1)
Recruitment Recruiting
Gender both
Phase Phase Ib/II
Variant Requirements No
Sponsors Phosplatin Therapeutics
Indications

lung non-small cell carcinoma

prostate cancer

breast cancer

transitional cell carcinoma

head and neck squamous cell carcinoma

Therapies

Avelumab + Imifoplatin

Age Groups: adult senior

No variant requirements are available.